16490-02-1

Basic information

• Product Name: 4,6-PYRIMIDINE DICARBOXYLIC ACID
• Synonyms: 4,6-PYRIMIDINE DICARBOXYLIC ACID;NSC 44347
• CAS NO: 16490-02-1
• Molecular Formula: C₆H₄N₂O₄
• Molecular Weight: 168.11
• Mol File: 16490-02-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 238-240℃
• Boiling Point: 497.4 °C at 760 mmHg
• Flash Point: 254.6 °C
• Appearance: /
• Density: 1.665±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 1.04E-10mmHg at 25°C
• Refractive Index: 1.638
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.14±0.10(Predicted)
• CAS DataBase Reference: 4,6-PYRIMIDINE DICARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-PYRIMIDINE DICARBOXYLIC ACID(16490-02-1)
• EPA Substance Registry System: 4,6-PYRIMIDINE DICARBOXYLIC ACID(16490-02-1)

Safety Data

• Hazardous Substances Data: 16490-02-1(Hazardous Substances Data)

Usage

Description

4,6-Pyrimidinedicarboxylic Acid, a chemical compound belonging to the family of pyrimidine dicarboxylic acids, is characterized by its unique structure and properties. It is an organic compound with the molecular formula C6H4N2O4, featuring a pyrimidine ring with two carboxyl groups attached at the 4th and 6th positions. 4,6-PYRIMIDINE DICARBOXYLIC ACID is known for its potential applications in various fields, particularly in the pharmaceutical and chemical industries.

Uses

Used in Pharmaceutical Industry:
4,6-Pyrimidinedicarboxylic Acid is used as a key building block for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a versatile component in the development of new drugs with potential therapeutic applications.
Used in Chemical Industry:
In the chemical industry, 4,6-Pyrimidinedicarboxylic Acid serves as an important intermediate for the production of various chemical compounds. Its reactivity and structural properties make it a valuable precursor in the synthesis of a wide range of products.
Used in Inhibitor Scaffolds:
4,6-Pyrimidinedicarboxylic Acid is used as a crucial component in the preparation of inhibitor scaffolds that target the human 2-oxoglutarate-dependent JMJD2 subfamily of histone demethylases. These inhibitors play a significant role in regulating gene expression and have potential applications in the treatment of various diseases, including cancer.

InChI:InChI=1/C6H4N2O4/c9-5(10)3-1-4(6(11)12)8-2-7-3/h1-2H,(H,9,10)(H,11,12)

Upstream product

• 1558-17-4 4,6-dimethylpyrimidine 
• 62501-45-5 4,6-dimethylpyrimidine-2(1H)-thione hydrochloride 
• 4472-44-0 2-chloro-4,6-dimethylpyrimidine 
• 6345-43-3 pyrimidine-4,6-dicarboxylic acid dimethyl ester 

Downstream Products

• 289-95-2 PYRIMIDINE 
• 15719-64-9 methylammonium carbonate 
• 6345-43-3 pyrimidine-4,6-dicarboxylic acid dimethyl ester 
• 50345-29-4 4,6-di-(hydroxymethyl)pyrimidine 
• 135002-40-3 pyrimidine-4,6-dicarboxylic acid bis(benzylamide) 
• 1206479-99-3 PMX₅₁₉ 
• 1224096-02-9 pyrimidine-4,6-dicarboxylic acid bis-{[3-amino-2-((R)-1-(tert-butoxycarbonyl)pyrrolidin-3-yloxy)-5-trifluoromethyl-phenyl]amide} 
• 1257443-69-8 (R)-6-(1-(biphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylcarbamoyl)pyrimidine-4-carboxylic acid 
• 690998-35-7 6-(4-fluoro-3-methyl-benzylcarbamoyl)-pyrimidine-4-carboxylic acid 

Relevant articles and documents

Radiolabeled Selective Matrix Metalloproteinase 13 (MMP-13) Inhibitors: (Radio)Syntheses and in Vitro and First in Vivo Evaluation

The noninvasive imaging of MMP activity in vivo could have a high impact in basic research as well as in clinical applications. This approach can be established using radiolabeled MMP inhibitors (MMPIs) as tracers for the detection of activated MMPs by means of PET. However, the complexity of diseases associated with dysregulated MMP expression necessitates the imaging of distinct MMPs or MMP subgroups to distinguish their individual role in specific diseases. To this end, selective and potent MMP-13 inhibitors based on a N,N′-bis(benzyl)pyrimidine-4,6-dicarboxamide core have been synthesized and successfully radiolabeled with carbon-11, fluorine-18, and gallium-68. Selected radiolabeled candidates were evaluated in vitro and in vivo regarding their pharmacokinetic properties and metabolic stability.

HISTONE LYSINE DEMETHYLASE INHIBITORS

The invention provides a compound which is an iV-oxalylglycine derivative of formula (I): a hydroxamic acid derivative of formula (II): or a heteroaryl derivative of fomula (III): wherein n; Z1; Z2; Y1; Y2; A; p; X1; X2; m; R4; B; R5; R6; R7; R8; R9; X3; R10; R11 and R12 are as defined herein, or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of the human 2-oxoglutarate-dependant JMJD2 subfamily of histone demethylases, in particular JMJD2E. Such inhibitors are useful in changing the epigenetic state of cells resulting in the inhibition / activation of chromatin remodelling, multiple gene activation / deactivation, and in treating cancer and other conditions characterised by undesirable cellular proliferation, and psychiatric disorders including depression.

Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib

This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.